What is the 13F Pro Quality Score for HOLX?

13F Pro ranks HOLOGIC INC (HOLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HOLX's current score at https://13fpro.ai/research/HOLX (free sign-up required for the full ranking).

Which hedge funds own the most HOLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HOLX include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/HOLX as soon as new 13F filings post.

Where does 13F Pro source HOLX data?

All HOLOGIC INC fundamentals and ownership data come directly from SEC EDGAR. HOLOGIC INC files with the SEC under CIK 859737. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HOLX in?

HOLOGIC INC (HOLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HOLX research updated on 13F Pro?

HOLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

HOLOGIC INC(HOLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 859737 HOLX stock profile & AI dashboard →

13F Pro Quality Score

62.3/100

Rank #750 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

32.4/100

Profitability

73.7/100

Balance Sheet

75.8/100

Earnings Quality

32.2/100

Free Cash Flow

77.8/100

Institutional Flow

62.0/100

Revenue Scale

75.1/100

Dilution Risk

40.9/100

HOLX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HOLOGIC INC (HOLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HOLX at 62.3/100 on a 32-signal composite quality model, placing it at rank #750 of 2,879 stocks — the top half of the AI-ranked universe. HOLX scores in the top quartile across free cash flow (77.8), balance sheet strength (75.8), revenue scale (75.1). Areas of concern include earnings quality (32.2) and revenue growth (32.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 40.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), HOLOGIC INC reports quarterly revenue of $1.0B, net income of $179.1M, an operating margin of 22.6%. Top institutional holders of HOLX by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. HOLX trades on the Nasdaq exchange and files with the SEC under CIK 859737. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HOLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HOLOGIC INC directly from SEC EDGAR. HOLOGIC INC's 13F Pro composite quality score has ranged between 8 and 81 since 2021, currently 62.3 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about HOLOGIC INC

Quirks, history, and lore behind HOLX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · mid-to-large cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of $3–4 billion, built almost entirely on products used by OB-GYN offices and radiology suites across the country.
3
The History
Founded in the 1980s, it transformed from a small diagnostics firm into a dominant force after a landmark acquisition that put it at the center of the breast cancer screening market.
4
The Secret
Its biggest competitive moat is a patented 3D mammography technology — called tomosynthesis — that it turned into the new standard of care and licensed aggressively to protect its turf.
5
The Lore
It also leads the market in minimally invasive gynecological surgery tools and is one of the rare medtech companies that focuses almost exclusively on women's health.
6
The Giveaway
If your doctor ordered a 3D mammogram or a ThinPrep Pap test, this Marlborough, MA company made the machine and probably the slide — it basically owns the annual women's wellness visit.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.0B

Net Income

Q1 2026

$179.1M

Free Cash Flow

Q1 2026

$215.2M

Operating Margin

Q1 2026

22.6%

ROIC

Q1 2026

3.1%

D/E Ratio

Q1 2026

0.48

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.7% YoY

$4.10BFY 2025

FY22 $4.86BFY23 $4.03BFY24 $4.03BFY25 $4.10B

Net Income

-28.3% YoY

$565.7MFY 2025

FY22 $1.30BFY23 $456.0MFY24 $789.5MFY25 $565.7M

Operating Income

-19.1% YoY

$714.3MFY 2025

FY22 $1.64BFY23 $668.4MFY24 $882.6MFY25 $714.3M

EPS (Diluted)

-25.0% YoY

$2.49FY 2025

FY22 $5.13FY23 $1.83FY24 $3.32FY25 $2.49

Total Assets

-1.5% YoY

$9.01BFY 2025

FY22 $9.07BFY23 $9.14BFY24 $9.16BFY25 $9.01B

Total Debt

-1.1% YoY

$2.52BFY 2025

FY22 $2.85BFY23 $2.83BFY24 $2.55BFY25 $2.52B

Op. Cash Flow

-17.7% YoY

$1.06BFY 2025

FY22 $2.13BFY23 $1.05BFY24 $1.29BFY25 $1.06B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.10B +1.7%	$4.03B -0.0%	$4.03B -17.1%	$4.86B -13.7%	$5.63B +49.1%	$3.78B
Net Income	$565.7M -28.3%	$789.5M +73.1%	$456.0M -65.0%	$1.30B -30.4%	$1.87B +67.8%	$1.12B
Operating Income	$714.3M -19.1%	$882.6M +32.0%	$668.4M -59.2%	$1.64B -33.9%	$2.48B +124.5%	$1.10B
EPS (Diluted)	$2.49 -25.0%	$3.32 +81.4%	$1.83 -64.3%	$5.13 -28.8%	$7.21 +71.3%	$4.21
Total Assets	$9.01B -1.5%	$9.16B +0.2%	$9.14B +0.8%	$9.07B +1.7%	$8.92B +24.0%	$7.20B
Total Debt	$2.52B -1.1%	$2.55B -10.1%	$2.83B -0.5%	$2.85B -6.6%	$3.05B -0.4%	$3.06B
Operating Cash Flow	$1.06B -17.7%	$1.29B +22.3%	$1.05B -50.5%	$2.13B -8.8%	$2.33B +159.9%	$896.6M

Get alerted when HOLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HOLOGIC INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HOLX

BlackRock, Inc.
$1.7B22,520,444 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.1B14,503,914 sh
STATE STREET CORP
$755.2M9,990,906 sh
HBK INVESTMENTS L P
$740.8M9,800,000 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$727.2M9,620,600 sh
FIL Ltd
$591.2M7,821,581 sh
GEODE CAPITAL MANAGEMENT, LLC
$456.3M6,058,845 sh
MILLENNIUM MANAGEMENT LLC
$427.2M5,651,225 sh
UBS Group AG
$384.7M5,089,745 sh
BALYASNY ASSET MANAGEMENT L.P.
$357.0M4,722,968 sh

Fund	Value	Shares
BlackRock, Inc.	$1.7B	22,520,444
VANGUARD CAPITAL MANAGEMENT LLC	$1.1B	14,503,914
STATE STREET CORP	$755.2M	9,990,906
HBK INVESTMENTS L P	$740.8M	9,800,000
VANGUARD PORTFOLIO MANAGEMENT LLC	$727.2M	9,620,600
FIL Ltd	$591.2M	7,821,581
GEODE CAPITAL MANAGEMENT, LLC	$456.3M	6,058,845
MILLENNIUM MANAGEMENT LLC	$427.2M	5,651,225
UBS Group AG	$384.7M	5,089,745
BALYASNY ASSET MANAGEMENT L.P.	$357.0M	4,722,968

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HOLX on your watchlist

Track score changes the day HOLOGIC INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HOLX a good stock to buy?

13F Pro's AI-powered analysis of HOLOGIC INC (HOLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HOLX are available on the HOLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HOLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HOLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HOLOGIC INC's investment landscape.